<DOC>
	<DOCNO>NCT02747979</DOCNO>
	<brief_summary>A prospective , randomize , control open clinic trial evaluate effect safety combination conventional hemodialysis ( HD ) hemoperfusion ( HP ) middle molecule removal complication improvement long-term maintenance hemodialysis ( MHD ) patient . There two phase study subject . Phase 1 ( screen phase ) . During phase , potential subject evaluate determine he/she eligible study . Phase 2 ( intervention phase ) . Each subject randomly allocate HD+HP ( HA130 per week ) group , HD+HP ( HA330 per week ) group HD group . The follow-up duration 3 month .</brief_summary>
	<brief_title>The Effect Safety Hemodialysis Hemoperfusion Severe Renal Osteopathy Itching Uremia Patients</brief_title>
	<detailed_description>All patient recruit center meet inclusion criterion randomly allocate HD+HP ( HA130 per week ) group , HD+HP ( HA330 per week ) group HD group . The follow-up duration 3 month . Hemoperfusion perform HA130 HA330 resin adsorbent . Blood flow 200ml/min，dialysate flow 500ml/min， hemodialysis hemoperfusion last 2.5h，continue HD remove adsorbent complete 4 hours'treatment.Heparin anticoagulation ：first pulse 0.5-1mg/kg ，appending 8-10mg/h . Primary endpoint improvement clinic symptom , meanwhile secondary endpoint serum β2MG、iPTH、CRP、ADMA、BMP2 decrease compare baseline , life quality , nutrition condition , cardiovascular ( CVD ) incidence .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<criteria>Willingness sign inform consent Stable haemodialysis treatment 3 month , undergo 2 3 time haemodialysis week 4 5 hour per session middle large molecule retention define immunoreactive parathyroid hormone ( iPTH ) &gt; 400 pg/mL , β2MG &gt; 5000 pg/ml、CRP &gt; 10mg/l . Refractory pruritus , carpal tunnel syndrome , restless leg syndrome , hyperparathyroidism refratory complication . Incapable reluctant sign inform consent comply schedule . platelet ( PLT ) count＜60×109/L disturbance coagulation , tendency severe bleed acute bleeding . Severe hypotension heart lung insufficiency Known hypersensitive contradiction intolerance dialyzer adsorbent Attend clinic trial recent 30 day</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>hyperparathyroidism</keyword>
	<keyword>refractory pruritus</keyword>
	<keyword>ostalgia</keyword>
	<keyword>insomnia</keyword>
	<keyword>CVD incidence</keyword>
	<keyword>life quality</keyword>
</DOC>